DOCSLIB.ORG

Illumina Pacbio: Provisional Findings Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Illumina Pacbio: Provisional Findings Report Anticipated acquisition by Illumina, Inc. of Pacific Biosciences of California, Inc. Provisional findings report 24 October 2019 © Crown copyright 2019 You may reuse this information (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit www.nationalarchives.gov.uk/doc/open-government- licence/ or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected]. The Competition and Markets Authority has excluded from this published version of the provisional findings report information which the inquiry group considers should be excluded having regard to the three considerations set out in section 244 of the Enterprise Act 2002 (specified information: considerations relevant to disclosure). The omissions are indicated by []. Some numbers have been replaced by a range. These are shown in square brackets. Contents Page Provisional Findings ................................................................................................... 4 1. The reference ....................................................................................................... 4 2. The industry .......................................................................................................... 4 Introduction to DNA sequencing ........................................................................... 4 Applications of DNA sequencing ........................................................................... 6 History of DNA sequencing ................................................................................... 8 Other suppliers of DNA sequencing .............................................................. 13 Beijing Genomics Institute (BGI) .................................................................... 14 Oxford Nanopore Technologies (ONT) .......................................................... 15 Thermo Fisher Scientific (Thermo Fisher) ..................................................... 16 QIAGEN N.V. (QIAGEN) ............................................................................... 17 Spend on DNA sequencing ................................................................................. 18 3. The Parties ......................................................................................................... 19 Illumina ............................................................................................................... 19 Overview of structure and operations ............................................................ 19 Financials ...................................................................................................... 20 PacBio ................................................................................................................ 24 Overview of structure and operations ............................................................ 24 Financials ...................................................................................................... 25 4. The Proposed Merger ......................................................................................... 28 Introduction ......................................................................................................... 28 Timeline of discussions ....................................................................................... 28 Rationale ............................................................................................................. 29 5. Relevant merger situation ................................................................................... 30 Enterprises ceasing to be distinct ....................................................................... 30 Jurisdiction test ................................................................................................... 31 Provisional conclusion on the relevant merger situation ..................................... 32 6. Counterfactual..................................................................................................... 32 Introduction and legal framework ........................................................................ 32 Views of the Parties ............................................................................................ 33 PacBio’s views ............................................................................................... 34 Illumina’s views .............................................................................................. 37 Third party views ................................................................................................. 38 CMA assessment ................................................................................................ 38 Market context ............................................................................................... 38 Assessment of failing firm arguments ............................................................ 39 Considerations which would not exist in the counterfactual ........................... 45 Provisional conclusions ................................................................................. 46 7. Market definition.................................................................................................. 46 Introduction and overview ................................................................................... 46 Product market definition .................................................................................... 48 Sequencing systems ..................................................................................... 48 Short read and long read sequencing ............................................................ 50 Non-NGS methods of ascertaining genetic information ................................. 59 Sequencing services ..................................................................................... 63 Conclusion on product frame of reference ..................................................... 66 Geographic market definition .............................................................................. 66 The Parties’ views ......................................................................................... 66 1 Evidence from third Parties ........................................................................... 67 Our assessment ............................................................................................ 67 8. Competitive effects of the merger ....................................................................... 68 Introduction ......................................................................................................... 68 Theory of Harm ................................................................................................... 68 Nature of competition .......................................................................................... 69 NGS Systems customers .............................................................................. 69 Competition beyond the ‘use case’ level ....................................................... 70 Dimensions of competition ............................................................................ 80 Price setting ................................................................................................... 82 Conclusion on nature of competition ............................................................. 84 Evidence of competition between the Parties and with competitors.................... 85 The Parties’ views ......................................................................................... 85 Market shares ................................................................................................ 98 Overview of internal documents evidence ................................................... 100 Illumina’s internal documents ...................................................................... 101 PacBio’s internal documents ....................................................................... 116 Evidence from customers ............................................................................ 125 Evidence from competitors .......................................................................... 135 Sales and sales forecasts ............................................................................ 140 Our assessment of the competitive effects of the Proposed Merger ................. 142 The structure of the market is highly concentrated ...................................... 143 Current competition between the Parties ..................................................... 144 Future competition between the Parties ...................................................... 146 Potential competition from Illumina in long read .......................................... 149 Constraint from other competitors ............................................................... 150 Provisional conclusion ...................................................................................... 153 Overall provisional finding ................................................................................. 156 9. Countervailing factors ....................................................................................... 156 Barriers to entry and expansion ........................................................................ 157 Introduction .................................................................................................
Load more

Recommended publications
  • BGI at a Glance EN20190626
    AT A GLANCE BACKGROUND The Human Genome Project (HGP) is considered one of the greatest scientific achievements of the last century. BGI was founded in 1999 in order to participate in this significant research project. Since then, BGI has become a world-leading life science organization. SERVICES BGI leads innovative development in genom- ics and life sciences through its integrated model incorporating industry development, ed- ucation and research in compliance with inter- national bioethical protocols, and applies fron- tier multi-omics research findings to areas in- cluding medicine, healthcare, resource con- servation, forensics and more; and provides cutting-edge proprietary life science instruments and devices, technical support and solutions to accelerate industry transfer of genomic technologies and revolu- tionize current healthcare system towards precision medicine and precision healthcare, using "omics" to benefit the mankind. CORE CAPABILITIES Research BGI·Research 24 2200+ 1200+ Innovation Centers SCI Publications Patent Applications (including 1 national and 7 provincial) Sequencing Services BGI·Genomics Reproductive Health Cancer Prevention Infectious Diseases and Treatment Advanced Tools in Life Sciences MGI Fully automated scale data production Oct. 2018: launched the ultra-high-throughput sequencer MGISEQ-T7 and the high-throughput automated sample preparation system MGISP-960 Oct. 2017: launched high-throughput genetic sequencers MGISEQ-2000 and MGISEQ-200, MGIFLP modular NGS workstation，and MGI- US-R3 robotic ultrasound system Nov. 2016: launched the BGISEQ-50 desktop sequencing system Oct. 2015: launched the BGISEQ-500 high-throughput desktop sequencing system Jun. 2015: launched the RevolocityTM sequencing system Jul. 2014: launched the BGISEQ-1000 sequencing system Mar. 2013: successful acquisition of a U.S.
    [Show full text]
  • Details Subject to Change. MGI Workshop Part 1
    MGI Workshop Part 1: Dr. Kwong Wai Choy (Richard) Associate Professor, Dept of Obstetrics & Gynaecology, Deputy Director, Prenatal Genetic Diagnosis Centre, The Chinese University of Hong Kong Bio: Dr. Choy obtained his BSc degree in Biomedical Sciences from the University of Bradford and M(Med)Sc in Immunology at University of Birmingham, UK. He received postgraduate training in genetics and was awarded Doctor of Philosophy by The Chinese University of Hong Kong in 1999. Dr. Choy’s main research interests include the development of novel molecular diagnostic strategies and innovative applications of molecular analysis tools in prenatal diagnosis. His current research focuses on (1) structural genomic variation (including copy number variants); (2) development and application of the microarray-based Comparative Genomic Hybridization (array CGH) and massively parallel sequencing technology for prenatal diagnosis. In 2007 he founded the Agilent microarray core facilities in CUHK, which is the first centre of its kind in Asia dedicated to prenatal diagnosis with a focus on molecular basis of normal and abnormal fetal development. Dr. Choy is an Honorary Scientific Officer (medical) at the New Territories East Cluster of Hospitals, Hong Kong, where he is involved in the delivery of the laboratory diagnostic service. He is also the board member of the Hong Kong Society of Medical Genetics since 2009. Title: Low-Pass Genome Sequencing versus Chromosomal Microarray Analysis: Implementation in Prenatal Diagnosis Abstract: Emerging studies suggest that low-pass genome sequencing (GS) provides additional diagnostic yield of clinically significant copy-number variants (CNVs) compared with chromosomal microarray analysis (CMA). However, a prospective back-to-back comparison evaluating accuracy, efficacy, and incremental yield of low-pass GS compared with CMA is warranted.
    [Show full text]
  • High-Throughput Low-Cost DNA Sequencing Using Surface-Coating Technology
    High-throughput low-cost DNA sequencing using surface-coating technology Yanzhe Qin ( [email protected] ) BGI-shenzhen Stephan Koehler Harvard University Shengming Zhao BGI-shenzhen Ruibin Mai MGI Tech Co., Ltd. Zhuo Liu MGI Tech Co., Ltd. Hao Lu MGI Tech Co., Ltd. Chengmei Xing BGI-shenzhen Biological Sciences - Article Keywords: next-generation sequencers, surface coating technology, reagent layers Posted Date: June 28th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-130381/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/11 Abstract The speed, expense and throughput of genomic sequencing impose limitations on its use for time-sensitive acute applications, such as rare or antibiotic resistant infections, and large-scale testing that is necessary for population- wide source-tracing, as in the COVID-19 pandemic. A major bottleneck for increasing throughput and decreasing operating costs of next-generation sequencers (NGS) is the ow cell that supplies reagents for the biochemical processes; this subsystem has not signicantly improved since 2005. Here we report a new method for sourcing reagents based on surface coating technology (SCT): the DNA adhered onto a biochip that is directly contacted by a reagent-coated polymeric strip. Compared with ow cells, reagent layers are an order of magnitude thinner while both the reagent exchange rate and biochip area are orders of magnitude greater. For whole genome sequencing (WGS), these improvements reduce turn-around time from days to twelve hours, reduce cost from about $1000 to $15, and increase data throughput by orders of magnitude.
    [Show full text]
  • Beyond Four Bases: Epigenetic Modifications Prove Critical to Understanding E
    Base Modification Detection Case Study | November 2012 BEYOND FOUR BASES: EPIGENETIC MODIFICATIONS PROVE CRITICAL TO UNDERSTANDING E. COLI OUTBREAK Studies of the E. coli outbreak in Germany demonstrate the fundamental need for long-read sequencing and DNA base modification data. Using SMRT® sequencing technology, scientists were for the first time able to reveal some of the complex mechanisms underlying gene regulation processes in the organism. A newly published paper adds to insights generated in a 2011 study investigating last year’s deadly E. coli outbreak in Germany; together, they offer a fascinating new view of the mechanisms of gene regulation in a microbe. Dr. Eric Schadt, Chair of the Department of Genetics and Genomics Sciences and Director of the Institute for Genomics and Multiscale Biology at Mount Sinai School of Medicine, helped lead these efforts to elucidate the strain of E. coli responsible for the outbreak. “All these bugs living in us and around us are affecting us on a much deeper level than we’ve appreciated,” he says. “Even in a microorganism there are complex networks at play, and being able to study these on a genome-wide scale for the first time is really causing a revolution within the microbiology community.” The PacBio RS sequencing platform “has the throughput to completely finish these small microbial genomes in under a day,” Schadt says. Dr. Eric Schadt, Director of the Institute for Genomics and Multiscale Biology, Mount Sinai School of Medicine The papers are remarkable for different reasons. “Origins — and then pulling those together into a multiscale view of the E.
    [Show full text]
  • Scientific Program
    SHANGHAI • MAY 7-10 SCIENTIFIC PROGRAM 1999-2019 CELEBRATING 20 YEARS SCIENTIFIC PROGRAM Annual Meeting & Exhibits Qsep series Bio-Fragment Analyzer Qsep1：Equipped with 8-hole module for upgrade to 12-hole module Qsep100：Automated process for 1-100 samples Qsep400： Automated 4 samples process/run(High-throughput workow) Field Genetic research Pathogenic microorganism detection or typing Clinical diagnosis Sample QC for Next Generation Sequencing Drug Discovery & The third generations of sequencing Third party clinical examination Transgenic animal and plant testing Application gDNA & total RNA & Fragmented DNA & micro-RNA & mRNA & ct/cf DNA QC NGS/SMRT QC CRISPR-Cas gene knockout analysis STR/SSR PCR/ Multiplex PCR product analysis High-resolution pathogen typing Nucleic Acid Extraction - Nucleic Acid QC Integration Service 18S rRNA 28S rRNA IColumn 12/24 Automated DNA/RNA Purication System tRNA ,5.8S RNA, Spin-column method; snRNA,etc. Ease of use, Ready to go, Wide applications; Streamline workow to avoid any cross contamination. 177 20 EzMate Automated Pipetting System 1000 PCR/qPCR sample preparation; HLA typing; SNP detection; DNA/RNA normalization; 354 NGS sample preparation; Protein normalization. Qsep100 Bio - Fragment Analyzer Automated process for 1-100 samples; Rapid analysis; High sensitivity; High resolution. HANGZHOU HOUZE BIO-TECHNOLOGY CO., LTD Website: www.bioptic.com.tw E-mail: [email protected] Tel：0571-81060645 Tel: +886-2-2218-8726 Web：www.houzebio.com Fax: +886-2-2218-8727 Address：Room 1101, 2th Building, No.158
    [Show full text]
  • Illumina Pacific Biosciences: Full Text Decision
    Anticipated acquisition by Illumina, Inc. of Pacific Biosciences of California, Inc. Decision on relevant merger situation and substantial lessening of competition ME/6795/18 The CMA’s decision on reference under section 33(1) of the Enterprise Act 2002 given on 18 June 2019. Full text of the decision published on 19 July 2019. Please note that [] indicates figures or text which have been deleted or replaced in ranges at the request of the parties or third parties for reasons of commercial confidentiality. SUMMARY 1. Illumina, Inc. (Illumina) has agreed to acquire Pacific Biosciences of California, Inc. (PacBio) for approximately £930.2 million (the Transaction). Illumina and PacBio are together referred to as the Parties or the Merged Entity. 2. The Competition and Markets Authority (CMA) believes that it is or may be the case that each of Illumina and PacBio is an enterprise; that these enterprises will cease to be distinct as a result of the Transaction; and that the share of supply test is met. Accordingly, arrangements are in progress or in contemplation which, if carried into effect, will result in the creation of a relevant merger situation. 3. The Parties overlap in the supply of DNA sequencing systems on a worldwide basis. The CMA has found that the product frame of reference should include both short read and native long read technologies on the basis that the available evidence, including the majority of third party submissions, industry reports and many of the Parties’ internal documents, all indicated a material (and increasing) overlap between these technologies for at least some use cases.
    [Show full text]
  • Title Authors Abstract Introduction
    Title MOSAIK: A hash-based algorithm for accurate next-generation sequencing read mapping Authors Wan-Ping Lee1, Michael Stromberg1,2, Alistair Ward1, Chip Stewart1,3, Erik Garrison1, Gabor T. Marth1 1 Department of Biology, Boston College, Chestnut Hill, MA 2 Illumina, Inc., San Diego, CA 3 Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA Abstract MOSAIK is a stable, sensitive and open-source program for mapping second and third-generation sequencing reads to a reference genome. Uniquely among current mapping tools, MOSAIK can align reads generated by all the major sequencing technologies, including Illumina, Applied Biosystems SOLiD, Roche 454, Ion Torrent and Pacific BioSciences SMRT. Indeed, MOSAIK was the only aligner to provide consistent mappings for all the generated data (sequencing technologies, low-coverage and exome) in the 1000 Genomes Project. To provide highly accurate alignments, MOSAIK employs a hash clustering strategy coupled with the Smith-Waterman algorithm. This method is well-suited to capture mismatches as well as short insertions and deletions. To support the growing interest in larger structural variant (SV) discovery, MOSAIK provides explicit support for handling known-sequence SVs, e.g. mobile element insertions (MEIs) as well as generating outputs tailored to aid in SV discovery. All variant discovery benefits from an accurate description of the read placement confidence. To this end, MOSAIK uses a neural-net based training scheme to provide well-calibrated mapping quality scores, demonstrated by a correlation coefficient between MOSAIK assigned and actual mapping qualities greater than 0.98. In order to ensure that studies of any genome are supported, a training pipeline is provided to ensure optimal mapping quality scores for the genome under investigation.
    [Show full text]
  • De Novo Transcriptome Sequencing and Gene Expression Profiling With/Without B-Chromosome Plants of Lilium Amabile Doori Park, Jong-Hwa Kim, Nam-Soo Kim
    www.genominfo.org eISSN 2234-0742 Volume 17 number 3, September 30, 2019 Aims and scope Genomics & Informatics is the official journal of the Korea Genome Organization (http://kogo.or.kr). Its abbreviated title is Genomics Inform. It was launched in 2003 by the Korea Genome Organization. It aims at making a substantial contribution to the understanding of any areas of genomics or informatics. Its scope includes novel data on the topics of gene discovery, comparative genome analyses, molecular and human evolution, informatics, genome structure and function, technological innovations and applications, statistical and mathematical methods, cutting-edge genetic and physical mapping, next generation sequencing and de novo assembly, and other topics that present data where sequence information is used to address biological concerns. Especially, Clinical genomics section is for a short report of all kinds of genome analysis data from clinical field such as cancer, diverse complex diseases and genetic diseases. It encourages submission of the cancer panel analysis data for a single cancer patient or a group of patients. It also encourages deposition of the genome data into designated database. Genome archives section is for a short manuscript announcing the genetic information of recently sequenced prokaryotic and eukaryotic genomes. These genome archives data can make the rationale for sequencing a specific organism. It is published and distributed quarterly at the last dates of March, June, September, and December. All submitted manuscripts will be reviewed and selected for publication after single blind review process. All manuscripts must be submitted online through the e-submission system available from: http://submit.genominfo.org.
    [Show full text]
  • Next Generation Sequencing for SARS-Cov-2
    Next generation sequencing for SARS-CoV-2 Next generation sequencing for SARS-CoV-2/COVID-19 Acknowledgements The PHG Foundation and FIND are grateful for the insight provided by the individuals consulted during the course of this work. Full consultee acknowledgements are listed in Appendix 1 Lead writers Chantal Babb de Villiers (PHG Foundation) Laura Blackburn (PHG Foundation) Sarah Cook (PHG Foundation) Joanna Janus (PHG Foundation) Emma Johnson (PHG Foundation) Mark Kroese (PHG Foundation) Concept development and lead review Swapna Uplekar (FIND) Reviewers Devy Emperador (FIND) Jilian Sacks (FIND) Marva Seifert (FIND) Anita Suresh (FIND) Report production PHG Foundation July 2020; Update March 2021 This report is the result of PHG Foundation’s independent research and analysis and is not linked to a third party in any way. PHG Foundation has provided occasional analytical services to Oxford Nanopore Technologies (ONT) as part of a consultancy agreement. Next generation sequencing for SARS-CoV-2 2 Contents Introduction 6 1.1 Methods 6 1.2 SARS-CoV-2 7 1.3 SARS-CoV-2 genome sequencing 8 1.4 SARS-CoV-2 biology 9 2 Global surveillance: applications of sequencing technologies and techniques 14 2.1 Overview of surveillance 15 2.2 Overview of genomic surveillance 17 2.3 Sequencing initiatives across the globe 18 2.4 Sequencing data repositories and data sharing 25 2.5 SARS-CoV-2 genomic data releases by country 26 2.6 Additional sequencing related initiatives 29 3 Diagnostics and the role of sequencing 32 3.1 Sequencing for diagnosis 32 3.2
    [Show full text]
  • Thailand Taking Off to New Heights Vol 28
    Vol. 28 l No. 1 l April 2018 THAILAND TAKING OFF TO NEW HEIGHTS BOI Net Application 02 Company Interview 08 BGI - A global pioneer Cover Story 03 in next generation sequencing Thailand Taking off to New Heights News Bites 09 Special Topic 05 SMART Visa - Attracting talent BOI’s Missions 10 through the smart program and Events Short Article 07 Thailand Economy 11 Thailand 2018 - Ready for business At-A-Glance to take off About BOI 12 BOI NET APPLICATION January - March 2018 FOREIGN INVESTMENT BY TARGET SECTORS Total Investment Digital Medical Petrochemicals 333 Projects 38 Projects 62.04 M 1 Project 0.06 M and Chemicals 9 Projects 111.97 M 6,399.59 Million Automotive Agriculture and Electronics 15 Projects 115.37 M Biotechnology 12 Projects 95.19 M 11 Projects 43.43 M Total Foreign Automation Tourism Food Processing Investment and Robotics 1 Project 1.26 M 5 Projects 26.71 M 215 Projects 1 Project 0.28 M 782.75 Million FOREIGN Sweden INVESTMENT 2 Projects 15.52 M Japan BY MAJOR 65 Projects ECONOMIES Netherlands 370.52 M 11 Projects South Korea 75.68 M 6 Projects United States 15.18 M 6 Projects China 37.18 M 23 Projects Hong Kong 89.13 M 12 Projects 85.51 M United Arab Emirates Taiwan 2 Projects THAILAND 10 Projects 17.72 M 22.09 M Singapore 30 Projects 63.04 M Unit: US$ (US$ = 31.82 THB) Note: Investment projects with foreign equity participation from more than one country are reported in the figures for both countries / Statistics on net applications are adjusted whenever applications are returned to applicants due to insufficient information.
    [Show full text]
  • Pacific Biosciences' 2020 Annual Report
    2020 Annual Report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¶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
    [Show full text]
  • Milken Institute Global Conference from Theappstore Orgoogleplay
    MISSION STATEMENT Our mission is to increase global prosperity by advancing collaborative solutions that widen access to capital, create jobs and improve health. We do this through independent, data-driven research, action-oriented meetings, and meaningful policy initiatives. 1250 Fourth Street 1101 New York Avenue NW, Suite 620 137 Market Street #10-02 Santa Monica, CA 90401 Washington, DC 20005 Singapore 048943 Phone: 310-570-4600 Phone: 202-336-8900 Phone: 65-9457-0212 #MIGLOBAL AGENDA | LOS ANGELES | APRIL 28 - MAY 1 E-mail: [email protected] • www.milkeninstitute.org download the Global Conference mobileapp download theGlobalConference descriptions and up-to-date programming information, information, descriptions andup-to-dateprogramming AT YOUR FINGER TIPS YOUR AT To find complete speaker biographies, panel findcompletespeakerbiographies, panel To SEE: requests andconnectwithparticipants requests CONNECT: speaker biographies,andvenuemaps Milken Institute Global Conference Global Institute Milken from the App Store orGooglePlay. theAppStore from CUSTOMIZE: the full agenda, panel descriptions, the fullagenda,paneldescriptions, and personalschedule opt-in to make meeting opt-in tomakemeeting your profile your profile MIGlobal WILSHIRE BOULEVARD WILSHIRE ENTRANCE 11 12 13 14 15 16 SALES & CATERING WELLNESS GARDEN CORPORATE EVENTS 21 CA WILSHIRE GARDEN TERRACE LOBBY EXECUTIVE GIFT SHOP BAR 17 18 19 20 OFFICES 4 Networking Areas 8 PAVILION LOUNGE VALET 22 7 5 Pavilion Lounge 9 6 Lobby Bar 10 Wilshire Garden Circa 55 (Lower Level)
    [Show full text]